Yazar "Oksuz, Mustafa Ferhat" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    A multicenter report of biologic agents for the treatment of secondary amyloidosis in Turkish rheumatoid arthritis and ankylosing spondylitis patients
    (Springer Heidelberg, 2016) Pamuk, Omer Nuri; Kalyoncu, Umut; Aksu, Kenan; Omma, Ahmet; Pehlivan, Yavuz; Cagatay, Yonca; Kucuksahin, Orhan; Donmez, Salim; Cetin, Gozde Yildirim; Mercan, Ridvan; Bayindir, Ozun; Cefle, Ayse; Yildiz, Fatih; Balkarli, Ayse; Kilic, Levent; Cakir, Necati; Kisacik, Bunyamin; Oksuz, Mustafa Ferhat; Cobankara, Veli; Onat, Ahmet Mesut; Sayarlioglu, Mehmet; Ozturk, Mehmet Akif; Pamuk, Gulsum Emel; Akkoc, Nurullah
    In this multicenter, retrospective study, we evaluated the efficacy and safety of biologic therapies, including anti-TNFs, in secondary (AA) amyloidosis patients with ankylosing spondylitis (AS) and rheumatoid arthritis (RA). In addition, the frequency of secondary amyloidosis in RA and AS patients in a single center was estimated. Fifty-one AS (39M, 12F, mean age: 46.7) and 30 RA patients (11M, 19F, mean age: 51.7) with AA amyloidosis from 16 different centers in Turkey were included. Clinical and demographical features of patients were obtained from medical charts. A composite response index (CRI) to biologic therapy-based on creatinine level, proteinuria and disease activity-was used to evaluate the efficacy of treatment. The mean annual incidence of AA amyloidosis in RA and AS patients was 0.23 and 0.42/1000 patients/year, respectively. The point prevalence in RA and AS groups was 4.59 and 7.58/1000, respectively. In RA group with AA amyloidosis, effective response was obtained in 52.2 % of patients according to CRI. RA patients with RF positivity and more initial disease activity tended to have higher response rates to therapy (p values, 0.069 and 0.056). After biologic therapy (median 17 months), two RA patients died and two developed tuberculosis. In AS group, 45.7 % of patients fulfilled the criteria of good response according to CRI. AS patients with higher CRP levels at the time of AA diagnosis and at the beginning of anti-TNF therapy had higher response rates (p values, 0.011 and 0.017). During follow-up after anti-TNF therapy (median 38 months), one patient died and tuberculosis developed in two patients. Biologic therapy seems to be effective in at least half of RA and AS patients with AA amyloidosis. Tuberculosis was the most important safety concern.
  • Küçük Resim Yok
    Öğe
    A Nationwide Experience with the Off Label Use of Interleukin 1 Targeting Treatment in Familial Mediterranean Fever Patients
    (Wiley, 2016) Akar, Servet; Cetin, Pinar; Kalyoncu, Umut; Karadag, Omer; Sari, Ismail; Cinar, Muhammed; Yilmaz, Sedat; Onat, Ahmet Mesut; Kisacik, Bunyamin; Erden, Abdulsamet; Balkarli, Ayse; Kucuksahin, Orhan; Oner, Sibel Yilmaz; Senel, Soner; Tufan, Abdurrahman; Direskeneli, Haner; Oksuz, Mustafa Ferhat; Pehlivan, Yavuz; Bayndir, Ozun; Keser, Gokhan; Aksu, Kenan; Omma, Ahmet; Kasifoglu, Timucin; Unal, Ali Ugur; Yildiz, Fatih; Balci, Mehmet Ali; Yavuz, Sule; Erten, Sukran; Ozgen, Metin; Sayarlioglu, Mehmet; Dogru, Atalay; Cetin, Gozde Yildirim; Alibaz-Oner, Fatma; Tezcan, Mehmet Engin; Pamuk, Omer Nuri; Onen, Fatos
  • Küçük Resim Yok
    Öğe
    The Psoriatic Arthritis Registry of Turkey: results of a multicentre registry on 1081 patients
    (Oxford Univ Press, 2017) Kalyoncu, Umut; Bayindir, Ozun; Oksuz, Mustafa Ferhat; Dogru, Atalay; Kimyon, Gezmis; Tarhan, Emine Figen; Erden, Abdulsamet; Yavuz, Sule; Can, Meryem; Cetin, Gozde Yildirim; Kilic, Levent; Kucuksahin, Orhan; Omma, Ahmet; Ozisler, Cem; Solmaz, Dilek; Bozkirli, Emine Duygu Ersozlu; Akyol, Lutfi; Pehlevan, Seval Masatlioglu; Gunal, Esen Kasapoglu; Arslan, Fatos; Yilmazer, Baris; Atakan, Nilgun; Aydin, Sibel Zehra
    Objective. The aim was to assess the characteristics of PsA, find out how well the disease is controlled in real life, demonstrate the treatments and identify the unmet needs. Methods. The PsA registry of Turkey is a multicentre Web-based registry established in 2014 and including 32 rheumatology centres. Detailed data regarding demographics for skin and joint disease, disease activity assessments and treatment choices were collected. Results. One thousand and eighty-one patients (64.7% women) with a mean (S.D.) PsA duration of 5.8 (6.7) years were enrolled. The most frequent type of PsA was polyarticular [437 (40.5%)], followed by oligoarticular [407 (37.7%)] and axial disease [372 (34.4%)]. The mean (S.D.) swollen and tender joint counts were 1.7 (3) and 3.6 (4.8), respectively. Of these patients, 38.6% were on conventional synthetic DMARD monotherapy, 7.1% were on anti-TNF monotherapy, and 22.5% were using anti-TNF plus conventional synthetic DMARD combinations. According to DAS28, 86 (12.4%) patients had high and 105 (15.2%) had moderate disease activity. Low disease activity was achieved in 317 (45.7%) patients, and 185 (26.7%) were in remission. Minimal disease activity data could be calculated in 247 patients, 105 of whom (42.5%) had minimal disease activity. The major differences among sexes were that women were older and had less frequent axial disease, more fatigue, higher HAQ scores and less remission. Conclusion. The PsA registry of Turkey had similarities with previously published registries, supporting its external validity. The finding that women had more fatigue and worse functioning as well as the high percentage of active disease state highlight the unmet need in treatment of PsA.